Business, energy, technology, markets and global industry news from Business News Today

VS-7375

PharmaDeviceNews VS-7375
Verastem Oncology advances its VS-7375 development programme as the TARGET-D 202 Phase 2 trial begins evaluating the investigational KRAS G12D inhibitor in previously treated advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?

Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.

Read More
Pharma & Biotech

Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?

Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.

Read More
Pharma & Biotech

Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets

Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.

Read More